Navigation Links
Investigational Drug May Reduce Involuntary Movements in People With Parkinson's Disease
Date:4/12/2011

HONOLULU, April 12, 2011 /PRNewswire-USNewswire/ -- Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9–16, 2011, in Honolulu.

"Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments could help patients who continue to experience tremors and involuntary movement problems," said study author Ravi Anand, MD, a consultant with Newron Pharmaceuticals in Bresso, Italy. "These results are an important step forward in understanding how safinamide impacts patients with severe Parkinson's disease. Symptoms of Parkinson's disease, motor fluctuations and dyskinesia can greatly affect a person's daily living and quality of life."

For the two-year study, 669 patients with mid-to-late stage Parkinson's disease who were already taking levodopa and other dopaminergic treatments were given 50 or 100 milligrams of safinamide per day or a placebo pill. Scientists tested participant's movement ability using the United Parkinson's disease rating scale that measures activities such as tremor, speech, behavior, mood and daily activities including swallowing, dressing and walking. A specific tool measuring severity of dyskinesia (DRS) was used in addition as primary efficacy endpoint.

At the start of the study, patients who took the 50 milligram dose of safinamide had an average score of 3.9 compared to a score of 3.4 for those taking a placebo pill. Patients who took the 100 milligram dose had an average score of 3.7.

After two years, researchers discovered in a post-hoc analysis that safinamide at 100 milligrams a day on top of taking levodopa reduced dyskines
'/>"/>

SOURCE American Academy of Neurology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
2. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
3. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
4. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
5. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
6. FDA Grants Orphan Drug Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
7. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
8. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
9. FDA Clears GeNO LLCs Investigational New Drug Application for Clinical Trials With Its NITROSYL™ Inhaled Nitric Oxide System
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... Mitsubishi Chemical Medience Corporation announced today that the ... 510(k) premarketing notification clearance to the PATHFAST® cTnI-II ... for its sale in the United States. The ... PATHFAST analysis system, a unique, self-contained, bench-top chemi-luminescence ...
... Reportlinker.com announces that a new market research ... Distributor Analysis of the Pharmaceutical ... http://www.reportlinker.com/p0552921/Distributor-Analysis-of-the-Pharmaceutical-Industry-in-Key-SADC-Countries.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... to present an overview of the pharmaceutical ...
Cached Medicine Technology:Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 2Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 3Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
(Date:10/22/2014)... 22, 2014 During the Western United ... supply runs dangerously low, Southern Oregon’s water is proving ... despite the lowest mountain snow pack on record in ... and early autumn.* That was the observation of journalist-hikers ... book “Hiking Southern Oregon,” during an interview with water ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... 2014 Although there are only 24 hours in ... people who have trouble finding time within their busy schedules for ... long periods of time to get in shape. Here are five ... the go. , Change Up Your Commute , Consider riding ... add some exercise into your daily routine. If you must use ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... and length may be showing a genetic propensity for obesity ... genes have been linked to increased body fat, but the ... lean muscle, the researchers said. At 1 year, kids ... 2 and 3, however, these genes were linked to excessive ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... Boston (Jan. 26, 2012) Research to Prevent Blindness ... specialist James Chodosh, M.D., M.P.H., a $150,000 Senior Scientific ... recognized scientists conducting eye research at medical institutions in ... respected for his work on viral infections of the ...
... of advanced head and neck cancer patients treated with ... positive outcomes than patients treated with radiation therapy alone ... according to a study presented at the Multidisciplinary Head ... and SNM., Researchers analyzed two subgroups totaling 410 patients ...
... to the anti-cancer drug erlotinib when it is administered before ... smoke, according to a study presented at the Multidisciplinary Head ... SNM., Erlotinib is an oral anti-cancer drug that can slow ... on the surface of the cancer cells. Early detection of ...
... Esposito HealthDay Reporter , WEDNESDAY, Jan. 25 (HealthDay ... known as mild cognitive impairment -- often precede Alzheimer,s disease, ... risk for these troubles than women. Lead researcher ... Olmsted County, Minn., who were between 70 and 89 years ...
... , WEDNESDAY, Jan. 25 (HealthDay News) -- U.S. ... depression and suicide, three new studies indicate. In ... war zone deployment in Iraq or Afghanistan, and found ... problems and alcohol and drug abuse. Nearly 14 ...
... fat and cholesterol before pregnancy were at higher risk for ... fat and cholesterol, according to researchers at the National Institutes ... a form of diabetes seen during pregnancy. Gestational diabetes ... in the newborn. Women whose diets were high in ...
Cached Medicine News:Health News:Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer 2Health News:Men at Higher Risk for Mental Decline That Precedes Alzheimer's 2Health News:Men at Higher Risk for Mental Decline That Precedes Alzheimer's 3Health News:U.S. Soldiers Face Host of Mental Health Issues 2Health News:U.S. Soldiers Face Host of Mental Health Issues 3Health News:High animal fat diet increases gestational diabetes risk 2
... OptiMumm™ smoke evacuator is ... complete smoke evacuation system ... AccuVac™ smoke evacuation attachment, ... and either the Force ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
Bone cement with Gentamicin 2.5%....
... Techno-Aide provides the highest level ... highest quality lead protective eyewear. ... + tolerance allowed. Mfg supervised by ... All lens meet or exceed standards ...
Medicine Products: